BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX ) is one of the 10 most shorted biotech stocks to buy according to hedge funds On March 2, Wedbush analyst Laura Chico increased the firm's price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $22 from $21. The analyst maintained her Outperform rating on the stock. Although the company had previously preannounced its fourth quarter results and FY26 guidance, additional details were provided following the completion of the Astria Therapeutics acquisition. Management maintained its forward guidance for FY26, along with the peak revenue targets. Chico views the company's commercial business as operating smoothly, with additional data from BCX17725 expected by the end of 2026. She continues to view the current setup for BioCryst shares favorably based on the company's ongoing commercial performance. BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush On February 26, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) repor
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Pharmaceuticals (BCRX) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "hold (c)".MarketBeat
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio [Yahoo! Finance]Yahoo! Finance
- BioCryst's First Profitable Year Recasts Hereditary Angioedema Growth Story [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 2/26/26 - Beat
BCRX
Sec Filings
- 3/16/26 - Form 144
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- BCRX's page on the SEC website